Assessing mortality in women with hepatitis C virus and HIV using indirect markers of fibrosis

AIDS

Volumn 26, Issue 5, 2011, Pages 599-607

  Bambha, Kiran ^a   Pierce, Christopher ^b   Cox, Christopher ^b   French, Audrey L ^c   Tien, Phyllis C ^a,i   Sharp, Gerald B ^d   Augenbraun, Michael ^e   Glesby, Marshall J ^f   Villacres, Maria C ^g   Plankey, Michael ^h   Strickler, Howard D ^j   Gange, Stephen J ^b   Peters, Marion G ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c Stroger Hospital   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e SUNY DOWNSTATE MEDICAL CENTER   (United States)

^f WEILL CORNELL MEDICAL COLLEGE   (United States)

^g UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^h GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

ⁱ SAN FRANCISCO VETERANS AFFAIRS MEDICAL CENTER   (United States)

^j ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Fibrosis markers; Hepatitis C virus; HIV; Longitudinal study; Mortality

Indexed keywords

ASPARTATE AMINOTRANSFERASE;

ADULT; ALL CAUSE MORTALITY; ANALYTICAL PARAMETERS; ARTICLE; ASPARTATE AMINOTRANSFERASE TO PLATELET RATIO INDEX; COHORT ANALYSIS; DIGESTIVE SYSTEM DISEASE ASSESSMENT; FEMALE; FIBROSIS 4 SCORE; FOLLOW UP; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIVER FIBROSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIXED INFECTION; MORTALITY RATE; MULTICENTER STUDY; NATIONAL HEALTH ORGANIZATION; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; BLOOD; CLINICAL TRIAL; HEPATITIS C; LIVER CIRRHOSIS; MIDDLE AGED; MORTALITY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; THROMBOCYTE COUNT; VIRUS LOAD;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ASPARTATE AMINOTRANSFERASES; FEMALE; FOLLOW-UP STUDIES; HEPATITIS C; HIV INFECTIONS; HUMANS; LIVER CIRRHOSIS; LONGITUDINAL STUDIES; MIDDLE AGED; PLATELET COUNT; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; VIRAL LOAD;

EID: 82755186461     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834fa121     Document Type: Article

References (25)

1. Koziel MJ, Peters MG. Viral hepatitis in HIV infection. N Engl J Med 2007; 356:1445-1454.
2. Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis 2001; 33:562-569.
3. Benhamou Y, Bochet M, Di MV, Charlotte F, Azria F, Coutellier A, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology 1999; 30:1054-1058.
4. Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group. N Engl J Med 1999; 340:1228-1233.
5. Weber R, Sabin CA, Friis-Moller N, Reiss P, El Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166:1632-1641.
6. Sulkowski MS, Mehta SH, Torbenson MS, Higgins Y, Brinkley SC, de Oca RM, et al. Rapid fibrosis progression among HIV/ hepatitis C virus-co-infected adults. AIDS 2007; 21:2209-2216.
7. Al Mohri H, Murphy T, Lu Y, Lalonde RG, Klein MB. Evaluating liver fibrosis progression and the impact of anti-retroviral therapy in HIV and hepatitis C coinfection using a noninvasive marker. J Acquir Immune Defic Syndr 2007; 44:463-469.
8. Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003; 38:518-526.
9. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology 2006; 43:1317-1325.
10. Barkan SE, Melnick SL, Preston-Martin S, Weber K, Kalish LA, Miotti P, et al. The Women's Interagency HIV Study. WIHS Collaborative Study Group. Epidemiology 1998; 9:117-125.
11. Hessol NA, Schneider M, Greenblatt RM, Bacon M, Barranday Y, Holman S, et al. Retention of women enrolled in a prospective study of human immunodeficiency virus infection: impact of race, unstable housing, and use of human immunodeficiency virus therapy. Am J Epidemiol 2001; 154:563-573.
12. French AL, Gawel SH, Hershow R, Benning L, Hessol NA, Levine AM, et al. Trends in mortality and causes of death among women with HIV in the US: A ten-year study. J Acquir Immune Defic Syndr 2009; 51:399-406.
13. Ruppert D, Wand, MP, Carroll RJ. Semiparametric regression. Cambridge Series in Statistical and Probabilistic Mathematics. Cambridge: Cambridge University Press; 2003.
14. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosisinchronic hepatitis C. Hepatology 2003; 38:1449-1457.
15. Rousselet MC, Michalak S, Dupre F, Croue A, Bedossa P, Saint-Andre JP, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257-264.
16. Skripenova S, Trainer TD, Krawitt EL, Blaszyk H. Variability of grade and stage in simultaneous paired liver biopsies in patients with hepatitis C. J Clin Pathol 2007; 60:321-324.
17. Regev A, Berho M, Jeffers LJ, Milikowski C, Molina EG, Pyrso-poulos NT, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002; 97:2614-2618.
18. Ishak KG. Chronic hepatitis: morphology and nomenclature. Mod Pathol 1994; 7:690-713.
19. Macias J, Giron-Gonzalez JA, Gonzalez-Serrano M, Merino D, Cano P, Mira JA, et al. Prediction of liver fibrosis in human immunodeficiency virus/hepatitis C virus coinfected patients by simple noninvasive indexes. Gut 2006; 55:409-414.
20. Kelleher TB, Mehta SH, Bhaskar R, Sulkowski M, Astemborski J, Thomas DL, et al. Prediction of hepatic fibrosis in HIV/HCV co-infected patients using serum fibrosis markers: the SHASTA index. J Hepatol 2005; 43:78-84.
21. Tural C, Tor J, Sanvisens A, Perez-Alvarez N, Martinez E, Ojanguren I, et al. Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus. Clin Gastroen-terol Hepatol 2009; 7:339-345.
22. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805.
23. Pugh RN. Pugh's grading in the classification of liver decompensation. Gut 1992; 33:1583.
24. den Brinker M, Wit FW, Wertheim-van Dillen PM, Jurriaans S, Weel J, van LeeuwenR, etal. Hepatitis B andC virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000; 14:2895-2902.
25. Nunes D, Fleming C, Offner G, Craven D, Fix O, Heeren T, et al. Noninvasive markers of liver fibrosis are highly predictive of liver-related death in a cohort of HCV-infected individuals with and without HIV infection. Am J Gastroenterol 2010; 105:1346-1353.